Estela Herrero-Sanchez

Madrid, MD 28049, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Optimized size exclusion chromatography demonstrates that extracellular vesicles are the key RNA carriers of ALK translocations in non-small cell lung cancer cell line secretome and patient plasma.

Optimized size exclusion chromatography demonstrates that extracellular vesicles are the key RNA carriers of ALK translocations in non-small cell lung cancer cell line secretome and patient plasma.

Journal: Extracellular vesicles and circulating nucleic acids

Published: February 03, 2025

Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.

Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.

Journal: Molecular oncology

Published: January 04, 2023

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation.

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation.

Journal: Cancers

Published: August 19, 2022

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 16, 2022

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis.

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis.

Journal: Frontiers in oncology

Published: May 13, 2022

Cancer as an infective disease: the role of EVs in tumorigenesis.

Cancer as an infective disease: the role of EVs in tumorigenesis.

Journal: Molecular oncology

Published: May 09, 2022

ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing.

ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing.

Journal: Clinical chemistry

Published: October 22, 2021

A simple immunoassay for extracellular vesicle liquid biopsy in microliters of non-processed plasma.

A simple immunoassay for extracellular vesicle liquid biopsy in microliters of non-processed plasma.

Journal: Journal of nanobiotechnology

Published: October 18, 2021

R-Score: A New Parameter to Assess the Quality of Variants' Calls Assessed by NGS Using Liquid Biopsies.

R-Score: A New Parameter to Assess the Quality of Variants' Calls Assessed by NGS Using Liquid Biopsies.

Journal: Biology

Published: August 03, 2021

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.

Journal: ESMO open

Published: April 06, 2021

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.

Journal: Molecular oncology

Published: January 13, 2021

ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma.

ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma.

Journal: Clinical chemistry and laboratory medicine

Published: October 02, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026